

## Investor briefing – Capital Raise

---

**21 February 2025**

**Melbourne, Australia, 21 February 2025:** 4DMedical Limited (ASX: 4DX, “4DMedical”, or the “Company”), a leader in respiratory imaging technology, is pleased to invite shareholders, investors and interested parties to its investor webinar hosted by the Managing Director and Chief Executive Officer, Dr Andreas Fouras.

4DMedical will hold an investor webinar on **Friday, 21 February 2025 at 10.30am AEDT (9.30am AEST)**, where Dr Andreas Fouras will provide an update on the Company’s recent announcement of its Placement and Share Purchase Plan.

### Investor Webinar Registration Details

An investor webinar with Dr Andreas Fouras, Managing Director and Chief Executive Officer of 4DMedical will be held at 10.30am AEDT (9.30am AEST) on Friday, 21 February 2025.

Please register in advance using the following links:

Phone registration: <https://s1.c-conf.com/diamondpass/10045637-gh76t5.html>

Webcast: <https://ccmediaframe.com/?id=RuOc7VLM>

After registering, you will receive a confirmation email containing information about joining the webinar or dial-in details for those who would prefer to join by telephone.

**–ENDS–**

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate

Chief Financial Officer

Simon Glover

[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

#### Administration

Company Secretary

Naomi Lawrie

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

### About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical’s innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the



company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of Imbio, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)